文献速递新发突发、热带与寄生虫病

四价登革疫苗CYD-TDV六年随访中住院及重症登革病例分析

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该事后分析评估了CYD-TDV三项 efficacy 研究六年随访中住院或重症经病毒学确诊登革(VCD)的风险。6-8岁血清阳性者亦观察到保护。临床特征和病毒血症水平组间可比。

要点

  • 疫苗保护在不同研究阶段均可见,最初2年最高。
  • 血清阳性6-8岁儿童也观察到住院和重症VCD风险降低。

核心结论

  • 在血清阳性且≥9岁参与者中,CYD-TDV在整个6年随访期内对住院和重症VCD提供稳健保护。
  • 血清阳性6-8岁参与者也观察到保护作用。

研究设计与样本

  • 对三项CYD-TDV efficacy研究(CYD14、CYD15、CYD23/CYD57)完整6年随访的事后分析。
  • 主要结局为按基线登革血清状态和免疫年龄(<9岁/≥9岁)分层的住院或重症VCD的风险比。

主要发现

  • 疫苗保护在不同研究阶段均可见,最初2年最高。
  • 住院VCD参与者的临床体征症状及量化登革病毒血症在组间可比。

临床怎么用

  • 对于既往登革暴露(血清阳性)且≥9岁的个体,CYD-TDV可提供针对住院和重症登革的长期保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Forrat R, Dayan GH, DiazGranados CA, et al. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. Clin Infect Dis. 2021. PMID: 33822015. doi:10.1093/cid/ciab288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。